Clinical Trial

A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight

Study acronym: RENEW 4
Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this clinical study is to look at how well a study medicine called cagrilintide helps people living with excess body weight to lose weight. Participants will either get cagrilintide, the active study medicine being tested or placebo, a medicine that has no active medicine in it. Which treatment participants get is decided by chance. Cagrilintide is a new medicine under development that doctors cannot prescribe yet, but it has been tested in humans before. Participants will be in this clinical study for about 9 months.
Trial Details
NCT Number NCT07745504
Lead Sponsor Novo Nordisk A/S
Conditions Overweight, Obesity
Enrollment 285 participants
Start Date 2026-08-04
Primary Completion 2027-05-18 (estimated)
Study Completion 2027-07-06 (estimated)
Updated on ClinicalTrials.gov 2026-08-04